We found higher expression of these IMs in patients with MM with immune-high microenvironment compared with those with immune-low microenvironment, such as the common immune checkpoint inhibitors (PD1, CTLA4, LAG3, TIGIT, TIM3, and BTLA) (34) (Figure S5). Here, TIGIT is linked to Miyoshi myopathy.